Copyright 2016 Bubalo Goode Sales & Cronen | All Rights Reserved.

Call 1-800-377-6841

As you fought breast cancer, did you also experience permanent hair loss from being prescribed Taxotere®?

Find out if you have a Taxotere® case.

We will contact you within 48 hours.

If you’ve experienced alopecia (permanent hair loss) or other hair loss symptoms after being administered Taxotere®, you may have a case.  Because this is a time-sensitive matter, it’s important you fill out the form now so that we can assess your case and contact you if we determine you qualify.

Who we are

When you choose a personal injury lawyer, you need to be represented by someone you can trust and who will treat your case with the importance that it deserves. At Bubalo Goode Sales & Cronen, we are driven by a single goal: to protect the rights of our clients.

This means getting clients the money and benefits that they deserve. We ensure that our clients are protected at every step of the claims process. We know that coping with an injury or disability is hard enough without added legal stress. Let us take the burden off your shoulders and navigate the legal system on your behalf.

We HAVE BEEN Driven by a single goal for over 30 years:
to protect the rights of our clients


Let's begin the process with a FREE case review. Submit the form above.

Taxotere® (docetaxel) was introduced by Sanofi-Aventis in 1996 for treatment of metastatic or locally advanced breast cancer along with other chemotherapy drugs. Sanofi-Aventis withheld information about the drug’s full effects from doctors and women with breast cancer.

  • Baldness or bald spots
  • Permanent hair loss
  • Thinning hair
  • Other problems with hair growth

You may be owed damages if you took Taxotere® and experienced:

Hair loss problems associated with Taxotere® and the lack of sufficient warnings.

Taxotere® is a member of a family of chemotherapy drugs known as Taxanes, which makes the chemotherapy hair loss problems more toxic. However, evidence suggests that Taxotere® provides no benefits greater than other available breast cancer treatments, such as Taxol.  

Instead of communicating warnings about the alopecia risk or issuing a Taxotere® recall, cancer victims filing legal action against Sanofi-Aventis maintain that it chose to withhold information from doctors and women with breast cancer, depriving them of the opportunity to make an informed decision about the Taxotere® risk of permanent hair loss.  The cancer victims making these claims allege that the drug makers placed their desire for profits ahead of the safety and well-being of women by continuing to make false and misleading statements in promotion of the drug.

In February 2009, the FDA sent a warning letter to Sanofi-Aventis, citing unsubstantiated claims the drug maker was making about the superiority of Taxotere® over Taxol, a drug with fewer and less severe side effects.  In addition, cancer victims have filed complaints against Sanofi-Aventis alleging that it appeared to have engaged in illegal and fraudulent marketing to push doctors to prescribe Taxotere® despite the alopecia risks.

Some of the charges listed in lawsuits against Taxotere® allege that the maker of this prescription drug used in the treatment of breast cancer has:

  • Failed to adequately warn about the risk of permanent hair loss following Taxotere® chemotherapy;
  • Failed to properly research the risk of alopecia with Taxotere® compared to Taxol and other breast cancer treatments;
  • Provided false and misleading statements about the “superior efficacy” of Taxotere®;

Engaged in illegal marketing and promotions to entice doctors to prescribe Taxotere®, despite the potential risk of hair regrowth problems;

Failed to update the warnings or recall Taxotere® after learning that as many as 1 of every 11 women treated with the drug experienced hair loss side effects that continue long after chemotherapy.

Chemotherapy is known to cause hair loss.  But the drug company distributing Taxotere® chose not to warn cancer victims that the drug may cause PERMANENT hair loss.  Taxotere was no more effective in fighting cancer than other drugs that did not cause permanent hair loss. The condition is called alopecia, another way of saying permanent hair loss and can be traumatic for women experiencing this unnecessary injury.

Multiple lawsuits have been filed alleging that misleading or even inaccurate information was provided to women suffering from breast cancer and the medical community that suggested hair lost from Taxotere® typically grows back. In contrast, studies, in addition to case reports, suggest that more than 9% of women treated with Taxotere® may experience persistent alopecia that continues, in some instances, for more than 10 years following their last use of the drug.

Taxotere® causes unnecessary permanent hair loss.